eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
1/2023
vol. 10
 
Share:
Share:
abstract:
Case report

D-dimer elevation during tranexamic acid therapy and the debate on the therapeutic approach in hereditary angioedema type I

Cansu Özdemiral
1
,
Deniz Cagdas
1

  1. Department of Immunology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
Alergologia Polska – Polish Journal of Allergology 2023; 10, 1: 63–67
Online publish date: 2023/03/14
View full text Get citation
 
PlumX metrics:
Hereditary angioedema type 1 (HAE-1) is the most prevalent HAE type, and it results from decreased antigenic C1 inhibitor (C1-INH) levels or function. Bradykinin-mediated angioedema in the face, trunk, extremities, genitalia, gastrointestinal tract, and upper airway are the symptoms of this rare and potentially fatal disease. PD-C1-INH concentrates, recombinant C1-INH, tranexamic acid (TXA), danazol, icatibant, ecallantide, and fresh-frozen plasma (FFP) may be used for treatment. The focus of this article is to point out D-dimer elevation during TXA use. We detected d-dimer elevation incidentally in 2 patients with hereditary angioedema (HAE) type 1 during tranexamic acid (TXA) therapy, in whom elevations were normalized a week after suspended TXA. However, the TXA treatment is expected to decrease D-dimer levels in surgery and hyperfibrinolysis. On the other hand, although using TXA in long-term prophylaxis in HAE treatment is not recommended, we observed that 2 patients had significant reduction of their attack frequency for over a year.
keywords:

angioedema, tranexamic acid, hereditary angioedema type I, D-dimer elevation



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.